CVS Health to pay $315 million to settle DOJ claims it filled unlawful opioid prescriptions

CVS Health agreed on October 13 to pay $315 million to resolve a Justice Department lawsuit alleging that its pharmacies filled unlawful prescriptions for opioids and other controlled substances and then billed federal health care programs for them. The government brought the claims under the Controlled Substances Act and the False Claims Act, covering conduct from October 2013 to December 2025.

The case began as a whistleblower suit filed by a former CVS employee, Hillary Estright, and the Justice Department filed its own complaint in December 2024. The share of the recovery that goes to the whistleblower has not yet been determined. As is typical in such settlements, the claims remain allegations: CVS did not admit wrongdoing and said it strongly disagrees with the government's case.

Alongside the payment, CVS signed a memorandum of agreement with the Drug Enforcement Administration. It commits the company to operate a hotline, proactively monitor its dispensing and evaluate prescribers whose orders look suspect. Early headlines described this as enhanced DEA oversight; the agreement itself sets compliance obligations for CVS rather than installing a DEA monitor.

Investors took the news in stride, with the stock flat in afternoon trading, a sign that the litigation cost was largely expected. The settlement removes one federal opioid case from CVS's docket, but it is a payment to resolve allegations, not a finding, and the compliance obligations will run alongside its normal pharmacy operations.